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FRET biosensor uncovers cAMP nano-domains
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Compartmentalized cAMP/PKA signalling is now recognized as important for physiology and
pathophysiology, yet a detailed understanding of the properties, regulation and function of
local cAMP/PKA signals is lacking. Here we present a fluorescence resonance energy transfer
(FRET)-based sensor, CUTie, which detects compartmentalized cAMP with unprecedented
accuracy. CUTie, targeted to specific multiprotein complexes at discrete plasmalemmal,
sarcoplasmic reticular and myofilament sites, reveals differential kinetics and amplitudes of
localized cAMP signals. This nanoscopic heterogeneity of cAMP signals is necessary to
optimize cardiac contractility upon adrenergic activation. At low adrenergic levels, and
those mimicking heart failure, differential local cAMP responses are exacerbated, with near
abolition of cAMP signalling at certain locations. This work provides tools and fundamental
mechanistic insights into subcellular adrenergic signalling in normal and pathological cardiac
function.
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P
hysical and emotional stress, via release of catecholamines,
activation of G-protein-coupled receptors (GPCRs) and
synthesis of 30-50-cyclic adenosine monophosphate
(cAMP), promotes a series of events, known as the fight-or-flight
response, aimed at avoiding potential harm. In the heart
this involves activation of b-adrenergic receptors (b-AR) and
consequent increases in heart rate (chronotropy), contractile
strength (inotropy) and relaxation rate (lusitropy), so that cardiac
output can be enhanced dramatically to support the increased
oxygen demands of the body. The main effector of cAMP, protein
kinase A (PKA), phosphorylates key targets in cardiac myocytes,
including L-type Ca2þ channels (LTCC) at the plasmalemma,
phospholamban (PLB) on the sarcoplasmic reticulum (SR), and
troponin I (TPNI) and myosin binding protein C (MyBPC) on
the myofilaments. These proteins participate in the coupling of
cell excitation to myocyte contraction, a process that is graded by
the concentration of intracellular [Ca2þ ] ([Ca2þ ]i) at each beat
and by adjusting the myofilament Ca2þ sensitivity1.
In addition to the b-AR fight-or-flight response, cAMP also
mediates signalling by numerous hormones, neurotransmitters
and GPCRs, and PKA can also phosphorylate numerous distinct
target proteins within the same cell. As a consequence, the cell
can potentially respond to a rise in cAMP with a multitude of
different, and sometimes opposing, effects2. Given the plethora of
PKA targets within the same cell, the appropriate physiological
response to a specific stimulus is achieved via compart-
mentalization of both GPCRs and the cAMP/PKA signal3.
Compartmentalized signalling allows different GPCRs to
generate unique spatially restricted cAMP pools4 that in turn
activate defined subsets of localized PKA5. Phosphodiesterases
(PDEs), the enzymes that degrade cAMP, play a key role in the
spatial regulation of cAMP propagation, and contribute to
defining boundaries of individual cAMP pools6,7. Selective
phosphorylation is often achieved through tethering of PKA
adjacent to specific targets via A kinase anchoring proteins
(AKAPs)8.
Multiple drugs currently in use for the treatment of various
conditions, including cardiac disease, target the cAMP/PKA
pathway. Given the compartmentalization of cAMP signals, a
detailed understanding of the actual organization, regulation and
function of individual cAMP compartments may allow targeting
individual (versus overall global cAMP in the bulk cytosol) cAMP
pools, to yield greater therapeutic specificity9. However, the size
and location of distinct cAMP domains, the amplitude and
kinetics of the cAMP signal within each domain, as well as the
specific functional role of individual domains remain largely
unknown.
Although real-time imaging of [cAMP] using fluorescence
resonance energy transfer (FRET)-based reporters has enhanced
our understanding of compartmentalized cAMP signalling4,10–12,
major drawbacks have been the limited resolution of existing
reporters and the difficulty in directly comparing cAMP signals
detected at different intracellular sites13. We use here a
combination of computational techniques to develop a novel
cAMP FRET-based sensor that can be targeted to different
macromolecular complexes, with equal cAMP sensitivities, to
afford direct comparison of cAMP signals at multiple subcellular
sites. Using this new tool we investigate local cAMP responses to
catecholamine in cardiac myocytes. By targeting this novel sensor
to key protein complexes that regulate excitation–contraction
coupling (ECC) we find that physiologically relevant cAMP
signals operate within the nanometer range. The cAMP signals
generated upon b-AR activation show remarkable and
unsuspected local heterogeneity, dictated by the activity of
PDEs. Such local coordination of the cAMP signal maximizes
b-AR-induced increases in contractility, but also mediates
opposing effects on the myofilament response to Ca2þ . Our
novel approach provides unprecedented accuracy and fidelity in
the detection of local cAMP signalling with direct applicability to
other cellular systems. We also offer original insight into the
regulation of fundamental mechanisms of cardiac contractility
with profound implications for the pathogenesis and treatment of
heart disease.
Results
Limitations of targeted Epac1-camps reporters. Our strategy to
study local cAMP signalling with high resolution was to target
multiple FRET reporters to distinct subcellular sites. We initially
fused the widely used cAMP FRET sensor Epac1-camps14 to
protein components of various multiprotein complexes. This
sensor features the FRET pair Yellow Fluorescent Protein- Cyan
Fluorescent Protein (YFP-CFP) at the amino- and carboxyl-
termini of the cyclic nucleotide binding domain (CNBD) of
the protein Epac1 (Fig. 1a). When expressed in CHO cells
and challenged with a saturating stimulus (FRSKþ IBMX) that
should produce similar maximal responses at all sites, the targeted
sensors exhibited variable maximal FRET changes. In the extreme
case, no detectable FRET change was seen with PDE4A1-Epac1-
camps, as previously reported15 (Fig. 1b). Thus, these sensors are
impractical for comparing cAMP signals at different targeted
cellular sites.
Design of a ‘universal’ FRET tag for cAMP. To overcome the
limitations of the Epac1-camps chimeras, we sought to design a
FRET sensor based on a novel topology that could potentially
serve as a ‘universal’ FRET moiety to tag proteins of interest
without affecting FRET sensor properties. We investigated mov-
ing YFP from the amino terminus of the sensor to minimize
potential interference from the targeting domain (TD) target
interaction with the FRET module. As the cAMP-sensing moiety
we chose the second CNBD of the regulatory subunit type IIb of
PKA (PKA-RIIb) (Supplementary Fig. 1a). Sequence conserva-
tion analysis (Supplementary Fig. 1b) led us to predict that loop
4–5 within this CNBD may be a suitable point to insert the YFP
with minimal risk of perturbing the folding of either the CNBD or
the YFP (Fig. 1c). We named this novel sensor CUTie (cAMP
Universal Tag for imaging experiments) to emphasize its versa-
tility in fusion proteins. Coarse-grained molecular dynamics
(MD) simulations of CUTie using the SIRAH force field16
predicted that in the presence of cAMP the distance between
CFP and YFP is 6.4 nm, resulting in an average FRET change
of 19% upon ligand binding (Supplementary Fig. 1c and
Supplementary Note 1).
Generation and characterization of CUTie. The construct for
expression of CUTie (Fig. 1c) was assembled and the reporter
expressed in CHO cells. Figure 1d shows a representative time
course of CUTie FRET change upon application of a saturating
stimulus. As predicted from MD simulations, and unlike Epac1-
camps, where binding of cAMP results in decreased FRET14,
cAMP binding to CUTie increases FRET (Fig. 1d, inset). The
sensitivity range and EC50 for cAMP (Fig. 1e) were determined by
measuring FRET changes in CHO cells expressing CUTie and in
which intracellular [cAMP] was equilibrated with known [cAMP]
in patch pipettes (after membrane rupture). Fusion of CUTie to a
number of targeting proteins (Fig. 1f) did not significantly alter
the kinetics or the maximal amplitude of the FRET change
(Fig. 1g), including fusion to PDE4A1, which had abolished FRET
when fused to Epac1-camps (Fig. 1b).
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Expression of targeted CUTie in cardiac myocytes. When
expressed in neonatal rat ventricular myocytes (NRVM) the
targeted CUTie reporters showed the expected specific localiza-
tion (Supplementary Fig. 2a). For further studies here we focused
on three key multiprotein complexes involved in ECC:
the AKAP18d/SERCA/PLB complex localized at the SR, regulat-
ing Ca2þ reuptake17; the myofilament-localized troponin
complex (TPNI/TPNT/TPNC) that regulates myofilaments
Ca2þ sensitivity18; and AKAP79/b-AR/adenylyl cyclase/LTCC
complex at the plasmalemma19 that regulates cAMP synthesis20
and LTCC Ca2þ influx21. Figure 2a shows the predicted
localization of CUTie fused to AKAP18d, TPNI and AKAP79.
When expressed in adult rat ventricular myocytes (ARVM),
correct localization of AKAP79-CUTie, AKAP18d-CUTie and
TPNI-CUTie was confirmed (Fig. 2b). Co-immunoprecipitation
of GFP and western blotting analysis confirmed that the targeted
sensors are part of the expected macromolecular complex in
ARVM (Fig. 2c) as well as in NRVM (Supplementary Fig. 2b).
Expression of targeted CUTie does not affect basal or b-AR-
stimulated myocyte responses (Fig. 2d and Supplementary
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Figure 1 | Generation of a universal FRET-tag for cAMP detection at specific macromolecular complexes. (a) Schematic representation of the targeted
Epac1-camps chimeras. CNBD, cyclic nucleotide binding domain; TD, targeting domain. (b) Representative kinetics of cAMP change (left panel) and
summary of the experiments performed (right panel) in CHO cells expressing untargeted Epac1-camps (EPAC1) or its targeted versions upon application
of the adenylyl cyclase activator forskolin (FRSK, 25mM) and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 100 mM),
a treatment that generates an intracellular amount of cAMP that saturates Epac1-cAMPs (ref. 27). AKAP18d, A-kinase anchoring protein 18d (ref. 17);
FXYD1, phospholemman; HSP20, heat shock protein 20; TPNI, troponin I; PDE4A1, phosphodiesterase 4A1. Bars show FRET change at saturation. NZ5
from at least five independent experiments, all samples are significantly different from each other by one-way ANOVA and Bonferroni post hoc test,
Pr0.05, except FXYD1-EPAC1 versus TPNI-EPAC1, which is not significant. (c) Top: schematic representation of CUTie. Bottom: ribbon representation of
the predicted molecular structures of CUTie in its cAMP-bound or cAMP-free forms. cAMP is shown in green. (d) Representative kinetics of FRETchange
and corresponding CFP and YFP emission intensity curves (inset) recorded in a CHO cell expressing CUTie and treated with a saturating stimulus.
(e) Concentration–response calibration curve generated using CHO cells expressing CUTie and microinfusion of known concentrations of cAMP via a patch
pipette. EC50¼ 7.4mM, sensitivity range between 0.5 mM and 50mM. Hill coefficient is 1.07. Broken line indicates maximal FRET change as predicted by
MD simulations. (f) Schematic representation of CUTie chimeras. For each concentration point NZ5 from at least five independent experiments.
(g) Representative kinetics of FRETchange (left panel) and mean maximal FRETchange (right panel) recorded at saturation. NZ10 from three independent
experiments. One-way ANOVA analysis with Bonferroni’s post hoc correction shows no significant difference between all samples. AKAP79, A-kinase
anchoring protein 79. All values are means±s.e.m.
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Fig. 2d,e). Critically, targeting of CUTie chimeras to myocyte
subcellular compartments does not affect the kinetics or the
maximal FRET change, both at saturating (Fig. 2e) and sub-
saturating cAMP concentrations (Supplementary Fig 2c–e). The
in-cell cAMP concentration–response curves for AKAP79-CUTie,
AKAP18d-CUTie and TPNI-CUTie are superimposable (Fig. 2f),
confirming equivalent cAMP sensitivity and dynamic range.
For AKAP79-CUTie EC50 is 7.17 mM and Hill coefficient is 1.23;
for AKAP18d-CUTie EC50 is 7.14 mM and Hill coefficient is 1.04;
for TPNI-CUTie EC50 is 7.24 mM and Hill coefficient is 1.15. The
sensors can therefore be used for direct comparison of cAMP
changes at the sites where they localize.
Differential local [cAMP] during b-AR activation. We next
tested cAMP responses to b-AR stimulation by isoproterenol
(ISO) in ARVM expressing AKAP79-CUTie, AKAP18d-CUTie
or TPNI-CUTie. Figure 3a–c shows that ISO (5 nM) induced
significantly smaller and more delayed cAMP response at TPNI
than at AKAP18d or AKAP79. Such heterogeneity in the cAMP
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response was detected over a range of ISO concentrations,
including at saturating concentrations (Supplementary Fig. 3).
Similar results were obtained in NRVM (Supplementary Fig. 4a–c).
The time course of ISO-dependent phosphorylation of TPNI and
PLB reflects the different kinetics of the cAMP response (Fig. 3d).
Notably, cAMP responses were synchronous and of similar
amplitude at the three sites when ISO was applied in the presence
of the PDE inhibitor IBMX (Fig. 3e–g and Supplementary
Fig. 4d–f) or the cells were treated with IBMX alone
(Supplementary Fig. 4d–f). Western blot analysis confirmed a
faster and increased phosphorylation of TPNI (and comparable to
PLB) upon IBMX treatment (Fig. 3h). Thus PDE activity is most
strongly limiting [cAMP] at TPNI versus SR or plasmalemmal
sites.
Maximal stimulated inotropy requires cAMP nanodomains.
PKA-dependent phosphorylation of LTCC and PLB causes larger
amplitudes of Ca2þ transient and contraction, whereas PKA-
mediated TPNI phosphorylation reduces myofilament Ca2þ
sensitivity and limits contraction amplitude. Both PLB and TPNI
phosphorylation contribute to speed up relaxation during b-AR
stimulation1. We hypothesized that differential regulation of
cAMP at these sites may be required to optimally coordinate
PKA-dependent phosphorylation to achieve maximal
enhancement of contraction and relaxation. To test this
hypothesis, we measured fractional shortening of ARVM in
response to cAMP generated by ISO (compartmentalized
signalling) or IBMX (homogeneous signalling) and measured
simultaneously in individual ARVM the bulk cytosolic cAMP
signal (assessed using the cytosolic, untargeted FRET reporter
EPAC-SH187 (ref. 22)). We found that application of 5 nM ISO
results in significantly larger increase in fractional shortening as
compared to 100mM IBMX (Supplementary Fig. 5a–e). We then
used a concentration of ISO (0.3 nM) that elicits a global cAMP
response, as detected by EPAC-SH187, similar to that resulting
from inhibition of PDEs with 100mM IBMX (Fig. 4a, top panel
inset). However, unlike 100 mM IBMX, which generates a clearly
detectable and equal FRET change at the three sites
(Supplementary Fig. 6b), 0.3 nM ISO generates a response that
is below the detection limit of the targeted sensors
(Supplementary Fig. 6a). When we measured simultaneously in
individual ARVM the bulk cytosolic cAMP signal and sarcomere
shortening on application of 0.3 nM ISO (Fig. 4a) or 100 mM
IBMX (Fig. 4b), we found that 0.3 nM ISO increased contractility
significantly more than 100 mM IBMX (Fig. 4a–d and
Supplementary Fig. 6c). Notably, the blunted inotropic effect of
IBMX is not due to a weaker Ca2þ response, because IBMX did
not limit the rise in Ca2þ transient amplitude versus ISO
(Fig. 4e,f and Supplementary Fig. 6d). Thus, with ISO we
observed a greater contractile benefit for the same Ca2þ
enhancement. That is consistent with lower local [cAMP] at
TPNI, weaker TPNI phosphorylation and higher myofilament
Ca2þ sensitivity with ISO.
Mathematical modelling of local cAMP signalling. To gain
additional mechanistic insight regarding differential myofilament
phosphorylation effects, we used a detailed cardiac myocyte
model of Ca2þ , ionic currents and contraction, which includes
cAMP-PKA-dependent signalling at nine known PKA targets
(including three myofilament targets, TPNI, MyBPC and titin).
This was obtained by incorporating our recent contractile
model23 into our mouse ventricular myocyte model24, to better
mimic experimental Ca2þ , contraction and PKA targets in rats
(Supplementary Fig. 7a and Supplementary Note 2). In the
baseline model, cAMP rises uniformly at all PKA targets upon
b-AR stimulation. This corresponds to the experimental case of
PDE inhibition with IBMX, whereby cAMP rises similarly at the
plasmalemma, SR and TPNI. Figure 5a, left shows that our model
agrees qualitatively with experimental data, with Ca2þ transient
and contraction amplitudes rising with IBMX (versus control) by
114% and 106%, respectively. To mimic the weak TPNI-CUTie
changes with ISO versus IBMX, we decreased the cAMP rise at
the myofilaments by 50% (TPNI, Titin and MyBPC). However,
this limited the increases in Ca2þ transient and especially in
contraction, compared to uniform [cAMP] (to 88% and 72%,
respectively), contrary to experiments in Fig. 4 where ISO
increased contraction by more than Ca2þ transients.
The model allows us to test the effect of attenuating cAMP
effects at any individual PKA target23, so we attenuated all three
myofilament targets individually and collectively (Supplementary
Fig. 7b). The only condition that showed a greater increase in
shortening versus Ca2þ transients was when only the TPNI effect
was reduced (myofilament Ca2þ desensitization), but the
MyBPC and titin effects responded fully (bar graphs in Fig. 5a
and Supplementary Fig. 7b). Indeed, in that case we found good
agreement between simulation and experiments, whereby ISO
versus IBMX increased Ca2þ transients less than contraction
(88 versus 113%, respectively; Fig. 5a, right). Thus, even within
the myofilaments there may be differential regulation of PKA-
dependent phosphorylation at TPNI, MyBPC and titin.
Figure 2 | Targeting of CUTie to cardiac myocyte subcellular sites. (a) Schematic representation of a portion of a cardiac myocyte in 2-D (left) and 3-D
(right). In the panel on the right three myofibrils are shown, for two of which the sarcoplasmic reticulum (SR) surrounding individual myofibrils is depicted.
The plasmalemma and its invaginations in T-tubules, which run along the Z-lines delimiting individual sarcomeres, are also shown. Colour shaded areas
indicate the expected localization of targeted reporters. For clarity, only representative areas have been shaded. AKAP79-CUTie (green) is targeted to the
surface of the plasmalemma facing the intracellular space; AKAP18d (red) is targeted to the network SR surrounding individual myofibrils where SERCA
also localize; TPNI-CUTie (yellow) localizes to the myofilaments constituting individual myofibrils, with exclusion of the Z-lines and the H zone. a-actinin
localizes to the Z-line. Dimensions are from (ref. 54), 3-D schematic representation modified from (ref. 55). (b) Confocal images of ARVM expressing
TPNI-CUTie, AKAP79-CUTie or AKAP18d-CUTie showing the localization of the sensor relative to the localization of a-actinin, wheat germ agglutinine
(WGA) and SERCA2, respectively. Scale bar: 10mm. A merge of two images and a magnified detail for each cell are also shown. On the right, the
fluorescence intensity profiles for the indicated targeted sensors (green) and the reference signal (red) are shown. Intensities were calculated along the line
indicated in the zoomed-in images. (c) Western blotting analysis of proteins in complex with targeted CUTie. ARVM were infected with adenovirus carrying
TPNI-CUTie, AKAP18d-CUTie or AKAP79-CUTie. Targeted CUTie chimeras and their interacting proteins were pulled down using GFP beads. Membranes
were probed with the antibodies indicated on the right of each panel. (d) Representative kinetics of sarcomere shortening recorded in ARVM expressing
the targeted CUTie sensors in basal conditions (left) and on application of ISO 1 nM (right). Representative of at least four biological replicates.
(e) Representative kinetics of cAMP change recorded in NRVM microinfused with 1mM cAMP and 100 mM IBMX via a glass pipette (left panel) and mean
maximal FRETchange±s.e.m. at saturation for all measurements performed (right panel). NZ10 from three biological replicates. No significant difference
by one-way ANOVA and Bonferroni’s post hoc test. (f) Concentration–response calibration curves generated by microinfusion of known concentrations of
cAMP in CHO cells stably expressing TPNI-CUTie, AKAP18d-CUTie or AKAP79-CUTie. For each concentration point NZ5.
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To test this prediction experimentally, we measured differences
in phosphorylation of TPNI, PLB and MyBPC with ISO versus
IBMX (Fig. 5b–d). We also used PKA inhibition (H89, 30mM)
and saturating activation to estimate minimal and maximal
phosphorylation levels. Addition of 0.3 nM ISO robustly
increased phosphorylation of both MyBPC and PLB, but not
TPNI (Fig. 5b–d). In contrast, raising [cAMP] globally with
100 mM IBMX resulted in strong phosphorylation for all three
targets. Together with the data at 5 nM ISO (Fig. 3a,b,e,f), these
results further confirm that ISO stimulation generates compart-
mentalized cAMP signals and differential PKA-mediated phos-
phorylation, with a blunted cAMP/PKA signal at TPNI compared
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Figure 3 | Differential regulation of the cAMP signal at different b-adrenergic targets. (a) Representative kinetics and summary (b) of FRET change
recorded in ARVM individually expressing AKAP18d-CUTie, TPNI-CUTie or AKAP79-CUTie in response to bath application of 5 nM ISO. One-way ANOVA
with Bonferroni’s post-hoc correction. (c) Delay from application of 5 nM ISO to first time point at which a FRET change was detected for all experiments
performed as in a. One-way ANOVA with Bonferroni’s post hoc correction. (d) Time course of TPNI (top) and PLB (bottom) phosphorylation on application
of 1 nM ISO to NRVMs. The level of phosphorylation on application of a saturating stimulus (SAT: 25 mM FRSKþ 100mM IBMX) for 10min is also shown.
NT, no treatment. N¼ 5 biological replicates. One-way ANOVA with Dunnett’s post hoc correction (all columns versus NT column). (e) Representative
kinetics and summary (f) of FRET change recorded in ARVM individually expressing AKAP18d-CUTie, TPNI-CUTie or AKAP79-CUTie in response to bath
application of 1 nM ISO in combination with 100mM IBMX. One-way ANOVA with Bonferroni’s post hoc correction. (g) Delay from application of 1 nM
ISOþ 100 mM IBMX to first time point at which a FRETchange was detected for all experiments performed as in e. (h) Time course of TPNI (top) and PLB
(bottom) phosphorylation on application of 100mM IBMX to NRVM. N¼ 5 biological replicates. One-way ANOVA with Dunnett’s post hoc correction
(all columns versus NTcolumn). Bars indicate means±s.e.m. For (b,c,f,g) NZ7 from at least N¼ 5 biological replicates. *Pr0.05, **Pr0.01, ***Pr0.001.
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to the other sites. The data strongly support the conclusion that a
smaller compartmentalized cAMP signal (as generated by 0.3 nM
ISO) is more effective in enhancing inotropy than a significantly
larger, homogeneous increase in cAMP (as generated by 100 mM
IBMX). The data also confirm the model predictions that limiting
TPNI phosphorylation allows greater increase in contraction for a
smaller increase in Ca2þ transients. The more gradual recruit-
ment of TPNI phosphorylation at higher levels of b-AR activation
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Figure 5 | Mathematical model of compartmentalized cAMP signalling. (a) Simulated cAMP rise (top), myocyte shortening (middle) and Ca2þ transient
(bottom) upon administration of IBMX or ISO at time¼0 s. Inset at the left shows baseline condition, and inset at right shows overlapping baseline
condition (grey) and steady-state response to cAMP increase. Bar graph in a shows the ratio of the increase in maximal shortening to increase in Ca2þ
transient amplitude induced by IBMX and ISO. (b) Western blotting analysis of cell lysates obtained from ARVM treated with H89 (30mM), vehicle
(CTRL), ISO (0.3 nM), IBMX (100mM) or 25 mM FRSKþ 100mM IBMX (SAT) for 10min. Membranes were probed for total and phosphorylated MyBPC
(b), TPNI (c) and PLB (d). Graphs show densitometric analysis and present the ratio value of phosphorylated to total protein expressed as percentage after
normalization to H89 treatment (taken as zero) and to maximal phosphorylation at saturation (taken as 100%). Values are means±s.e.m. *Pr0.05,
***Pr0.001. NZ8 independent experiments from at least five biological replicates. One-way ANOVA with Dunnett’s post hoc correction.
Figure 4 | Differential local regulation of cAMP signals is necessary for maximal stimulated inotropy. (a) Representative time course of global cytosolic
cAMP change (top) and sarcomere shortening (bottom) recorded simultaneously in the same ARVM expressing the cytosolic FRETreporter EPAC-SH187 on
application of 0.3 nM ISO or (b) 100mM IBMX. Inset at the top of a shows mean FRET change measured in ARVM expressing the cytosolic FRET reporter
EPAC-SH187 on application of 0.3 nM ISO or 100 mM IBMX. Bars are means±s.e.m., no significant difference by unpaired t-test. In a,b cells were paced at
1 Hz. Inserts at the bottom of a,b indicate sarcomere shortening kinetics averaged over the time interval indicated by the black bar. (c) Normalized mean
sarcomere shortening kinetics measured at steady state after the application of ISO (0.3 nM) or IBMX (100mM), as indicated. (d) Effect of 0.3 nM ISO or
100mM IBMX on sarcomere shortening measured in all experiments as shown in a,b. Shortening is expressed as percent increment over control (before the
stimulus) calculated as (D shortening/shorteningcontrol)  100, where D shortening¼ (shorteningstimulated–shorteningcontrol). Unpaired t-test. (e) Averaged
normalized Ca2þ transient recorded on application of 0.3 nM ISO or 100mM IBMX. NZ6. (f) Effect of 0.3 nM ISO or 100 mM IBMX on the amplitude of the
Ca2þ transient expressed as percent increase over control (before the stimulus). Unpaired t-test shows no significant difference. Bars are means±s.e.m.
*Pr0.05. For all experiments NZ6 from at least three biological replicates.
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may aid relaxation and assure diastolic relaxation under high
sympathetic tone, where higher heart rates limit diastolic time.
TPNI is selectively vulnerable to reduced adrenergic input.
Given the reduced [cAMP] rise at TPNI versus PLB on ISO
stimulation, we asked whether this subcellular compartment may
be particularly vulnerable in conditions such as cardiac hyper-
trophy and heart failure (HF) where the cAMP response to
catecholamine is blunted as a consequence of adrenergic desen-
sitization25. To address this question, we expressed the targeted
CUTie sensors in NRVM treated for 48 h with 10 mM
norepinephrine, a well-established in vitro model of cardiac
hypertrophy (Fig. 6a)26. As shown in Supplementary Fig. 8b the
in vitro hypertrophied myocytes exhibit an attenuated global
cAMP response to ISO. Detection of [cAMP] with the targeted
reporters revealed that whereas the response to 0.5 nM ISO at
TPNI is significant in control cells it is almost undetectable in
hypertrophic cells (Fig. 6b). Unexpectedly, we found that the
cAMP signal at AKAP79 and AKAP18d was not significantly
different in control versus hypertrophic cells (Fig. 6b), despite
global cAMP being significantly reduced (Supplementary Fig. 8b).
Application of 0.5 nM ISO in the presence of 100 mM IBMX
abolished any difference between subcellular compartments and
between control and hypertrophic cells (Fig. 6c).
We next probed the local cAMP response in hypertrophic
myocytes from rats subjected to minipump infusion of ISO for 7
days or failing myocytes from rats subjected to myocardial
infarction (MI) upon coronary artery ligation (the characteriza-
tion of these two in vivo models is summarized in Supplementary
Table 1). As shown in Fig. 6d and f, respectively, both ISO
infusion and MI result in a dramatic decrease in the cAMP
response at TPNI compared to the other sites. Interestingly, in
both in vivo models, the response at AKAP18d was also
significantly reduced compared to control cells, albeit to a lesser
extent (Fig. 6d,f), suggesting that additional mechanisms altering
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Figure 6 | Compartmentalized cAMP signalling in hypertrophic cells. (a) Localization of the targeted CUTie reporters in control (top) and hypertrophic
(bottom) NRVM. Scale bar: 10mm. Average cell size for control myocytes was 351.8±7.3 mm2 and for hypertrophic myocytes 674.9±14.8mm2 (NZ216
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the regulation of local cAMP signalling at the AKAP18d/PLB/
SERCA complex may come into play at later stages during the
myocardial remodelling process.
Using the concentration–response curves for cytosolic (Fig. 1e)
and targeted (Fig. 2f) CUTie in combination with an in-cell
calibration curve for PKA activation (Supplementary Fig. 9) we
can estimate the impact on PKA activity of the cAMP signal
generated at the sites studied. As summarized in Table 1, the
difference between the cAMP response and the resulting PKA
activation at TPNI and at the other compartments is exacerbated
by reduced adrenergic input. Importantly, while 0.5 nM ISO
applied to healthy NRVM results in significant activation of PKA,
it does not generate sufficient cAMP to activate PKA at TPNI in
hypertrophic cells. The same stimulus, however, generates
comparable activation of PKA at other sites both in healthy
and hypertrophic cells.
Discussion
We developed a new FRET-based sensor, CUTie, that affords
unprecedented fidelity and accuracy of detection of compart-
mentalized cAMP by quantitatively reporting and allowing direct
comparison of cAMP levels in the environment immediately
surrounding macromolecular complexes. This sensor offers a
general method for fine mapping of cAMP signals in any cellular
system. Although CUTie EC50 for cAMP is higher than for other
available cAMP FRET reporters27, its sensitivity range is within
physiological intracellular cAMP concentrations and adequate
to measure cAMP changes elicited by sub-nanomolar
b-adrenoceptor agonist.
We investigate the cardiac response to catecholamines and
focus on three complexes that regulate ECC: the AKAP18d/
SERCA/PLB complex at the SR, the AKAP79/b-AR/adenylyl
cyclase/LTCC complex at the plasmalemma and the troponin
complex at the myofilaments. We show that the cAMP signal
generated in response to b-AR stimulation differs at these three
sites in both amplitude and kinetics. Such heterogeneity does not
depend on the distance from the site of cAMP synthesis at the
plasmalemma, but relies on differential local cAMP degradation
by PDEs, as equal responses at the three sites are detected on
PDEs inhibition. Given the localization of the complexes involved
and the geometry of ARVM (Fig. 2a), an upper bound for the
dimension of the cAMP domains investigated here can be
estimated at 300 nm (based on the diameter of myofibrillar
bundles), at least one order of magnitude smaller than previously
thought4. Despite the small size of local cAMP nanodomains, the
plasmalemma (T-tubules) and free SR network, which are up to
1.1 mm apart, exhibit similar local cAMP responses at AKAP79
and AKAP18d. This suggests similar local cAMP tuning in these
regions (at least under normal conditions). In contrast, our results
suggest that differences in local regulation of cAMP may occur
within tens of nanometers within the myofilament structure,
between TPNI and MyBPC sites that are in very close physical
proximity.
We observe that different treatments can generate comparable
increases in bulk cytosolic cAMP (Fig. 4a, top panel inset) while
resulting in significantly different cAMP levels in the environ-
ment immediately surrounding individual macromolecular com-
plexes (Fig. 3a and Supplementary Fig. 4a,b). In addition, we find
that some specific sites (AKAP79 and AKAP18d), but not others
(TPNI), can exhibit robust increases in cAMP level even with
reduced adrenergic input (Fig. 6 and Table 1). Taken together
these findings indicate that global and local cAMP are
differentially regulated, and support a model whereby cytosolic
cAMP (‘bulk cAMP’) is less involved than are very local cAMP
nano-domains (‘physiologically relevant cAMP’) in regulating
function.
We show that maximal contractility is achieved when the
cAMP increase at TPNI is delayed and attenuated compared to
the cAMP response at AKAP79 and AKAP18d. Both mathema-
tical modelling and experimental evidence indicate that optimal
inotropy is achieved if the attenuated PKA-mediated phosphor-
ylation at the myofilaments selectively affects TPNI while
the level of phosphorylation of MyBPC is maintained high.
Interestingly, differential phosphorylation of TPNI and MyBPC
upon catecholamine stimulation was previously reported28,29
although the mechanism remained unclear. PKA activity
reporters targeted to plasmalemma, PLB and troponin T also
recently revealed domain differences in PKA activity, particularly
at the myofilaments30. Our findings here are compatible with a
model whereby TPNI and MyBPC are under the control of
distinct cAMP/PKA nano-domains, although it is also possible
that other kinases (for example, CaMKII, which also
phosphorylates MyBPC at S282 (ref. 31)) or reduced local
phosphatase activity may be responsible for the stronger
phosphorylation of MyBPC. It should be noted that TPNI
contributes significantly to lusitropy during isometric
contractions32 and therefore our measurements of unloaded
myocyte shortening are likely to underestimate the in vivo effect
of TPNI phosphorylation on relaxation kinetics.
PDE inhibitors are approved drugs for the treatment of HF,
where they are intended to correct defective cAMP signalling33.
Although administration of PDE inhibitors can promote short-
term inotropic responses, long-term functional improvement is not
sustained and their administration is associated with increased
mortality34. This has limited their utility to treatment of HF that is
not responding to alternative therapies. Our findings may explain
the long-term failure of this therapeutic approach, as PDE
Table 1 | cAMP concentration and PKA activity in different compartments of healthy and hypertrophic myocytes.
Control Hypertrophic
Stimuli 1 nM ISO 0.5 nM ISO 100lM IBMX 0.5 nM ISO
cAMP PKA cAMP PKA cAMP PKA cAMP PKA
Compartments
AKAP18d 5.8 45 3 13 5.1 37 2.6 9
TPNI 3.7 21 2.1 5 5 36 1.4 0
AKAP79 5.4 40 3.3 16 4 35 2.8 11
Bulk cytosol 4.1 26 2.6 9 3 14 1.6 2
Concentration of cAMP (mM) and increase in PKA activity over basal (expressed as percent of maximal activation) in untreated (control) and NE-treated (hypertrophic) NRVM at AKAP18d, TPNI,
AKAP79 and in the bulk cytosol. cAMP concentrations are calculated from FRETchanges as measured with AKAP18d-CUTie, TPNI-CUTie, AKAP79-CUTie or CUTie using the calibration curves shown in
Figs 1e and 2f. FRETchanges to calculate cAMP concentrations are from Supplementary Fig. 4b,e and Fig. 6b,c. For completeness, data for cAMP changes in the bulk cytosol in response to 1 nM ISO and
100mM IBMX are also shown. Increase in PKA activity is calculated from cAMP concentrations derived as above using the PKA activity calibration curve shown in Supplementary Fig. 9. Basal PKA activity
is set at 3% based on the in-cell PKA activity calibration curve.
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inhibition, by obliterating the difference between cAMP nano-
domains and reducing efficiency of contraction, effectively curtails
beneficial local cAMP controls to optimize contractility.
Here we demonstrate that the spatial heterogeneity of the
cAMP signal is accentuated in pathological stress conditions
(chronic b-adrenergic activation or post-MI), where acute
b-adrenergic induced [cAMP] elevation (within 2–6min) is
nearly abolished at TPNI, but well-preserved at plasmalemma
targets (AKAP79) and only slightly limited at the SR (AKAP18d).
It is well established that PKA-mediated phosphorylation of
TPNI reduces myofilament Ca2þ sensitivity35 and data support a
role for Ca2þ sensitization in diastolic dysfunction36, focal
energy deficits37 and arrhythmogenesis38. In addition, genetic
models with unphosphorylatable TPNI show enhanced
susceptibility to HF development under stress39–41, implicating
an increase in TPNI Ca2þ sensitivity as a cause of contractile
abnormality in the failing heart. Numerous studies have reported
a significant decrease in TPNI phosphorylation in failing hearts
versus control, both in animal models and in humans42,43, a
feature that has been shown to be associated with preserved PLB
phosphorylation44–46. b-Adrenergic downregulation and/or
upregulation of phosphatase activity47 or delocalization and
degradation of local PKA as a consequence of the remodelling
process44 have been suggested as possible mechanisms
responsible for defective TPNI phosphorylation. Our study
demonstrates an intrinsic propensity of the myocyte to Ca2þ
sensitization, as TPNI is selectively vulnerable to low
phosphorylation as a consequence of attenuated local cAMP
signalling. Thus, maximal contractility in response to stress is
achieved at the cost of increased tendency for myofilament Ca2þ
sensitization and diastolic dysfunction. Our findings may thus
explain the limited success of b-blocker therapy in HF with
preserved ejection fraction48 and suggest that therapeutic
interventions aimed at normalizing Ca2þ sensitivity may prove
beneficial in the treatment of HF, particularly in the early stages
of the pathological process. As local domains of cAMP are
regulated by the activity of specific PDE isoforms9, identification
of the PDE isoform(s) involved in attenuation of cAMP signals at
TPNI may provide a novel therapeutic target.
Methods
Generation of CUTie FRET sensor. The details of the rational design of the CUTie
sensor along with the computational methods applied to define the final protein
sequence are provided in the Supplementary material section. A DNA fragment
encompassing nucleotides 817–986 of the Rattus norvegicus protein kinase,
cAMP-dependent, regulatory subunit type II beta (Prkar2b) (NM_001030020.1)
(PDB ID: 1CX4) was PCR-amplified from cDNA and inserted between NheI and
AgeI restriction sites upstream of Enhanced Yellow Fluorescent Protein (EYFP) (PDB
ID: 1QY0), and a fragment encompassing nucleotides 987–1235 was PCR-amplified
and inserted between EcoRI and SalI restriction sites downstream EYFP in the
pEYFPc1 vector (Clontech Laboratories, CA, USA). Enhanced Cyan Fluorescent
Protein (ECFP) (PDB ID: 1QY0) including the stop codon was fused downstream of
nucleotide 1235 of the Prkar2b, between the SalI and BamHI restriction sites.
Generation of targeted reporters. Full length AKAPs 18, isoform d (AKAP18d)
(NM_001001801), FXYD domain containing ion transport regulator 1 (FXYD1)
(NM_001278718.1), heat shock protein, alpha-crystallin-related B6 (HSP20)
(BC068046.1), TPNI type 3 (cardiac) (TPNI) (BC099631), cAMP-dependent
protein kinase (AKAP79) (M90359.1) and cyclic AMP-specific phosphodiesterase
(PDE4A1) (L27062.1) were PCR-amplified to incorporate NheII and HindIII
restriction sites at their 50 and 30 ends, respectively. The resulting fragments were
individually cloned, in frame, into the NheII site 50 to the CUTie sensor, or into the
HindIII site 50 to the EPAC1-based FRET sensor14. Clones were screened for
correct orientation of insert and selected clones were sequenced. The TPNI- and
HSP20-targeted EPAC1 sensors were kindly provided by Prof G. Baillie, University
of Glasgow, UK. Adenoviral vectors carrying the targeted reporters were generated
by Vector BioLabs (Malvern, PA, USA).
In-cell calibration by microinfusion. A detailed protocol is described in ref. 49. In
brief, mycoplasma free CHO (Hamster Chinese ovary) cells (from Sigma-Aldrich,
UK) stably expressing the CUTie sensor were patch-clamped and monitored for
FRET ratio change (see below) simultaneously. After establishing a tight seal
between cellmembrane and patchpipette the whole-cell configuration was
established. In this configuration, providing a direct access from the pipette to the
cytoplasm, cAMP can either diffuse from the pipette into the cell or vice versa,
depending on the cAMP concentration in the pipette solution. The FRET ratio
changes elicited by a range of cAMP concentrations loaded into the patch pipette
were recorded, analysed offline and computed to generate dose-response curves.
All curves were corrected for quenching effects due to chloride in the pipette
solution. Seal, whole-cell and access resistances were continuously monitored
during the experiments. Seal resistances typically were in the range of several
Gigaohm, whole-cell resistances were between 0.5 and 1GO. Whole-cell access
resistance was in the range of 80–100 nS, as computed online by WinWCP (Vers.
4.1.2, Strathclyde Electrophysiology Software, John Dempster, University of
Strathclyde). Pipette solutions contained 20mM NaCl, 140mM KCl, 2mM MgCl2,
0.00404mM CaCl2, 0.1mM BAPTA and 10mM HEPES, supplemented with the
required amount of cAMP-Na. For cardiomyocyte measurements KCl was replaced
by 140mM K-glutamate. All patch-pipette solutions were adjusted to match the
intracellular pH. The extracellular solution contained 140mM NaCl, 3mM KCl,
3.2mM MgCl2, 2mM CaCl2, 15mM glucose, 10mM HEPES, and was adjusted
with NaOH to pH 7.2. To prevent swelling or shrinkage artefacts, osmolality values
of pipette and extracellular solutions were matched.
To determine the extent of PKA activation at different intracellular
concentrations of cAMP a similar approach as described above was used, with a
PKA-based FRET reporter4 where the R subunit is tagged with CFP and the C
subunit is tagged with YFP (see Supplementary Fig. 9a). On binding of cAMP to
the R-CFP subunit the C-YFP subunit dissociates and FRET is abolished. It should
be noted that this sensor displays identical sensitivity to cAMP-dependent
activation as the native, untagged PKA50 and can therefore be used to accurately
measure PKA activation in the cell. The reporter was expressed in CHO cell and
known concentrations of cAMP were delivered into the cells via a patch pipette
while measuring FRET changes as described above.
Isolation and culture of cardiomyocytes. ARVM were isolated from 350 to 375 g
male Sprague-Dawley rats as described51. Briefly, hearts were perfused on a
Langendorff apparatus at 37 C for 4–5min through the coronary arteries with an
oxygenated Ca2þ -free Tyrode Buffer solution (130mM NaCl, 5mM Hepes,
0.4mM NaH2PO4, 5.6mM KCl, 3.5mM MgCl2, 20mM taurine, 10mM glucose),
and subsequently digested with 0.06mgml 1 Liberase TH (Roche Diagnostics
Limited, UK) in a 100mM Ca2þ containing Tyrode buffer solution for a further
15–20min until the heart became flaccid. After perfusion, the left ventricle was
removed, minced and resuspended in equal volume of 1% BSA Ca2þ -free Tyrode
Buffer solution. Extracellular Ca2þ was added incrementally to reach a final
concentration of 1.0mM. Cells were cultured in Minimum Essential Medium
(MEM) (Sigma-Aldrich, UK), supplemented with 2.5% fetal bovine serum (FBS),
100 units per ml penicillin, 100mg perml streptomycin, 2mM L-glutamine and
9mM NaHCO3 and plated on laminin (40mgml–1) coated culture dishes. ARVM
were left to adhere for 2 h in a 5% CO2 atmosphere at 37 C, before the medium
was replaced with FBS-free MEM. Myocytes were infected for 3 h at multiplicity of
infection of 10–100 with adenovirus encoding for FRET reporters. The medium
was then replaced with fresh FBS-free MEM including 0.5 mM cytochalasin D (MP
Biomedicals, UK). Infected cells were kept in culture for less than 36 h. Sprague-
Dawley NRVM (2 days old) were cultured as described before4. For hypertrophy
induction, cells were cultured in serum-free MEM for 24 h prior to addition of
10 mM norepinephrine for 48 h (ref. 52).
In vivo models and echocardiography. All procedures were carried out in
compliance with the standards for the care and use of animal subjects as stated by
the requirements of the UK Home Office (ASPA1986 Amendments Regulations
2012) incorporating the EU directive 2010/63/EU. For the in vivo infusion of ISO,
male Sprague-Dawley rats (Charles River 310–360 g) were anaesthetized using
isoflurane and maintained on a heated pad with monitoring of temperature, pulse
oxygenation and ECG (MouseMonitor S, Indus Instruments). Mini-osmotic pumps
(model 2001, Alzet, USA) containing ISO (3mg per kg per day) dissolved in 0.05%
ascorbic acid (to prevent the formation of toxic oxidation products) were
implanted subcutaneously in the subscapular region, under isoflurane anaesthesia.
Control animals were implanted with pumps containing 0.05% ascorbic acid. Rats
were infused for 7 days. Echocardiographic indices were obtained according to the
recommendations of the British Society of Echocardiography. Transthoracic
echocardiography was performed in control and ISO-treated animals with the use
of a commercially available Vivid I echocardiography system (GE Healthcare)
using an 11.5MHz phased array 10 S-RS pediatric echo probe. Wall thickness and
LV dimensions were obtained from M-Mode measurements taken at the level of
the papillary muscles. ISO infusion caused the heart rate of the anaesthatized rats to
increase from B380 b.p.m. to 510 b.p.m. within 5min. The respiration rate
increased to B120 breaths per min and remained elevated for the 7 days. Echo-
cardiographic assessment of cardiac function after 7 days of treatment showed that
iso-treated rats had a significantly elevated heart rate (499±23 versus
355±26 b.p.m.) and ejection fraction (97±0.8 versus 88±0.9) compared with
sham controls. ISO-treated rat hearts were hypertrophied, with a significant
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increased thickness of the left ventricular interventricular septum and the posterior
wall (Supplementary Table 1).
For the MI procedure, 200–300 g Sprague-Dawley rats were housed individually
with access to food ad libitum following surgical procedures. After administration
of antibiotics and buprenorphine rats were anaesthetized, before undergoing a
thoracotomy and the removal of their pericardium. This allowed the ligation of the
left anterior descending coronary artery to induce myocardial infarction (MI).
Generally after 16 weeks end-stage heart failure was achieved. To confirm this the
ejection fraction was calculated from M-mode echocardiography recordings (Vevo
770 micro-imaging system, Visualsonics). End-stage heart failure was indicated by
an ejection fraction of less than 40%. Only animals achieving this level of heart
failure were sacrificed to allow isolation of myocytes as described.
No randomization was used. All experiments with cells from in vivo treatments
were conducted blind for the treatment.
Immunofluorescence staining. Twenty four hours after infection with AKAP18d-
CUTie or TPNI-CUTie adenovirus, ARVM were fixed in paraformaldehyde 4% for
15min, washed with PBS and permeabilized in 0.2% Triton X-100 for 30min.
After blocking with 1% BSA for 1 h, the cells were incubated with goat
anti-SERCA2 (c-20) (sc-8094, Santa Cruz Biotechnology, TX, USA, used at 1:100)
and a mouse anti-a-Actinin Sarcomeric (A7811, Sigma-Aldrich, UK, used at
1:2,000), respectively, at 4 C overnight. Samples were then washed with PBS-0.1%
Tween20 and incubated with anti-Goat IgG (Hþ L) Alexa Fluor 555 conjugate or
anti-Mouse IgG (Hþ L) Alexa Fluor 555 conjugate (A27017 and A-21425 Thermo
Fisher Scientific, MA, USA, both used at 1:1,000) for 60min at room temperature.
ARVM expressing AKAP79-CUTie were incubated with Wheat Germ Agglutinin,
Alexa Fluor 594 Conjugate (5mgml–1) (W11262, Thermo Fisher Scientific, MA,
USA) for 10min at 37 C before fixing the cells with formaldehyde 4%. The fixed
cells were rinsed in PBS-0.1% Tween20 and mounted in Ibidi Mounting Medium
(Thistle Scientific, UK). Images were acquired with an Inverted Olympus FV1000
confocal microscope.
Pull-down experiments. For pull-down experiments ARVM from one heart or
6 106 NRVM were plated onto 3 10-cm Petri dishes coated with laminin
(20 mgml–1) and infected with the indicated adenovirus for 3 h. The cells were
washed after 36 h with ADS buffer (106mM NaCl, 20mM Hepes, 0.8mM
NaH2PO4, 5.3mM KCl, 0.4mM MgSO4, 5mM glucose) and lysed in RIPA buffer
(Sigma-Aldrich, UK) supplemented with Complete EDTA-free protease inhibitor
cocktail tablets (Roche Diagnostics Limited, UK) for 5min on ice. The cells were
then collected and placed on a rotating wheel for 20min at 4 C. Insoluble material
was removed by centrifugation at 9,600g for 10min at 4 C and total protein was
quantified by Micro BCA Protein Assay Kit (Pierce Biotechnology Inc., IL, USA).
Seven hundred fifty milligrams of proteins were rotated for 2–4 h at 4 C with 30 ml
of agarose beads coated with a monoclonal anti-GFP antibody (GFP-Trap_A,
gta-10, ChromoTek GmbH, DE). The precipitates were then collected by cen-
trifugation at 16,000g for 3min and beads were washed five times with ice-cold
RIPA buffer. Bound proteins were then eluted in 25 ml of 2 SDS-loading buffer
(Life Technologies) and released from the beads at 95 C for 5min. Pulled down
proteins were resolved on Bolt 4–12% Bis-Tris Plus Gels (Thermo Fisher
Scientific, MA, USA) and transferred onto nitrocellulose membrane (Amersham
Protran 0.45mm, GE Healthcare Life Sciences, UK). After transfer, the membranes
were blocked for 1 h at room temperature in Protein-Free (TBS) Blocking buffer
(Thermo Fisher Scientific, MA, USA), and then incubated overnight at 4 C with
the following primary antibodies: goat anti-SERCA2 (c-20) (sc-8094, Santa Cruz
Biotechnology, TX, USA, used at 1:500); goat anti-Troponin T-C (c-19) (sc-8121,
Santa Cruz Biotechnology, TX, USA, used at 1:500) and Adenylyl Cyclase V/VI
(C17) (sc-590, Santa Cruz Biotechnology, TX, USA, used at 1:200). After five
washes with TBS-0.5% Tween20 (Alfa Aesar, MA, USA) membranes were
incubated at room temperature for 2 h with appropriate horseradish peroxidase-
conjugated secondary antibodies and detected with ECL western blotting detection
kit (Thermo Fisher Scientific, MA, USA). The blots were stripped with stripping
buffer (Thermo Fisher Scientific, MA, USA) and reprobed with anti-glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) antibody (sc-1666574, Santa Cruz
Biotechnology, TX, USA, used at 1:500) to detect protein contamination and with
anti-GFP antibody (sc-9996, Santa Cruz Biotechnology, TX, USA, used at 1:1000)
to control for efficient pull-down. For all experiments at least three biological
replicates were used.
Western blot analysis. 2 106 NRVM were plated onto 6-cm Petri dishes coated
with laminin (40 mgml–1) and treated as described above. After 48 h cells were
washed with a modified Ringer saline solution and then treated at room
temperature with ISO 1 nM alone, IBMX 100mM alone and FRSK 25mMþ IBMX
100mM as indicated. Cells were lysed using ice-cold RIPA buffer supplemented
with Complete EDTA-free protease inhibitor cocktail tablets and PhosSTOP
Phosphatase Inhibitor Cocktail Tablet (Roche Diagnostics Limited, UK) on ice and
gently agitated for 20min. Protein concentrations were determined by Micro BCA
Protein Assay Kit (Pierce, Rockford, IL). Samples equivalent to 8–30 mg proteins
were separated on Bolt 4–12% Bis-Tris Plus Gels after blocking with 5% Phospho
Blocker milk (Cell Biolabs Inc., San Diego, CA, USA) for 1 h at room temperature
membranes were incubated overnight at 4 C with phosphor-specific rabbit
anti-TPNI phospho (Ser22þ 23) antibody (1:2,000, ab58545 Abcam, UK) rabbit
anti-PLB phospho (Ser16) antibody (1:4,000, A010-12, Badrilla, UK), anti-MyBPC
phospho (Ser282) antibody (1:2,500, kindly provided by Dr Sakthivel Sadayappan,
Department of Cell and Molecular Physiology, Loyola University Chicago, IL).
The blots were washed and incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies for 2 h at room temperature. Immunoreactive
bands were visualized by ECL western blotting detection kit. Antibody dilutions
and exposure times were adjusted to ensure that for each antibody the signal
detected was within the linear range. Membranes were then stripped of bound
antibodies by incubation with stripping buffer for 45min at room temperature with
gentle agitation. The blots were reprobed with mouse anti-TPNI (1:2,000,
ab19615 Abcam, UK), mouse anti-PLB (1:4,000, A010-14 Badrilla, UK), mouse
anti-MyBPC3 (1:1,000, sc-137237 Santa Cruz Biotechnology, TX, USA) for loading
controls. Quantification of the band intensity was accomplished by densitometry
using ImageJ software (http://rsbweb.nih.gov/ij/index.html). The extent of
protein phosphorylation was calculated as the ratio of the density of the band
corresponding to the phosphorylated protein to the density of the band
corresponding to total protein. The values were subsequently normalized using
GraphPad Prism software (GraphPad Software, Inc., CA, USA), defining zero as
the density after H89 treatment (lowest phospho/total ratio) and 100% as
the density at saturation (FRSK 25 mMþ IBMX 100mM treatment, highest
phopho/total ratio) for each data set. Densities measured for the other treatments
are expressed as a percentage relative to the saturating treatment. Uncropped scans
of films are shown in Supplementary Fig. 10.
Intracellular Ca2þ dynamics. Isolated ARVM were plated onto laminin
(40 mgml–1) coated coverslips and cultured overnight. Cells were loaded with 1 mM
Fura-2 AM (Molecular Probes, OR, USA) in the dark at room temperature for
15min and then washed three times. Coverslips were mounted in the perfusion
chamber, continuously perfused with a Tyrode solution containing 1.4mM Ca2þ
at 37 C, and paced at 1Hz using a field stimulator (Myopacer; IonOptix, Milton,
MA). When at steady state, cells were perfused with ISO 0.3 nM or IBMX 100 mM
for about 10min. The background-subtracted Fura-2AM emission at 510 nm was
recorded and expressed as a ratio of fluorescent light on excitation at 340 and
380 nm (R340/380). The recorded transients were analysed using the IonWizard
software (IonOptix, Milton, MA).
FRET imaging. FRET imaging experiments were performed 24–48 h after trans-
duction with adenovirus carrying each sensor, as described before53. Cells were
maintained at room temperature in a modified Ringer solution (125mM NaCl,
20mM Hepes, 1mM Na3PO4, 5mM KCl, 1mM MgSO4, 5.5mM glucose, CaCl2
1mM, pH 7.4). ARVM were imaged 18 h after infection and kept at B35 C in
Tyrode solution containing 1.4mM Ca2þ . An inverted microscope (Olympus
IX71) with a PlanApoN, 60 , NA 1.42 oil immersion objective, 0.17/FN 26.5
(Olympus, UK), was used. The microscope was equipped with a CoolSNAP HQ2
monochrome camera (Photometrics) and a DV2 optical beam-splitter (MAG
Biosystems, Photometrics). Images were acquired and processed using MetaFluor
7.1, (Meta Imaging Series, Molecular Devices). FRET changes were measured as
changes in the background-subtracted 480 nm/545 nm fluorescence emission
intensity on excitation at 430 nm and expressed as R/R0, where R is the ratio at time
t and R0 is the average ratio of the first 8 frames. FRET imaging experiments with
ARVM isolated from MI rats and age-matched controls were performed using an
ORCA-ER CCD camera (Hamamatsu Photonics, Welwyn Garden City, UK)
attached to an inverted microscope (Nikon TE2000) equipped with a 30 Watt
dia-illuminator. The system has an EX436/20 excitation filter combined with
DM455 dichroic mirror.
Sarcomere shortening. ARVM with resting sarcomere lengths between 1.50 and
1.80 mm were examined for shortening dynamics. Experiments were performed
using an inverted microscope (Olympus IX71) with a PlanApoN, 40 , NA 1.30 oil
immersion objective. Myocytes were imaged by using the transillumination light
path equipped with an additional red filter and recorded by a MyoCam-S CCD
video camera (IonOptix Milton, MA). Cells were electrically stimulated at 1Hz in
the presence of 1.4mM Ca2þ at 35±1 C. Amplitude and velocity of sarcomere
shortening/relengthening was measured and analysed using the video-based sar-
comere length detection software module of IonWizard (IonOptix Milton, MA).
Parameters from 10 contractions were averaged to minimize beat-to-beat variation
and obtain mean values at baseline (control) and for the response to stimulus.
A separate cohort of myocytes were infected with Ad-EPAC-SH187 (ref. 22) and
used to measure simultaneously sarcomere shortening and FRET. Cells plated onto
laminin-coated coverslips were mounted in a metal chamber and kept in Tyrode
solution containing 1.4mM Ca2þ at 35±1 C. FRET and shortening images were
separated by an additional beam splitter (600 nm HP dichroic mirror, Cairn, Kent,
UK) in the emission path and acquired simultaneously by a CoolSNAP HQ2 and
MyoCam, respectively. The two cameras were connected to separate PCs to run the
acquisition in parallel. FRET was performed as described above. In our experiments
the simultaneous acquisition of shortening data did not affect the quality of the
FRET acquisitions. After FRET and contractility signals reached the steady state
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(after about 2min), ISO 0.3 nM or IBMX 100 mM were directly applied into the
bath solution. Sarcomere shortening amplitude values before and after the stimuli
were used to determine the percentage increase of stimulated shortening.
Mathematical modelling and simulation. We developed a mouse ECC in silico
model by embedding the Negroni et al. five-state contraction model23 within the
well-established Morotti–Grandi24 mouse ventricular action potential, Ca2þ and
b-adrenergic signalling model. In the Supplementary Notes, we provide more
details on the model formulation describing the merging of the models and
emphasizing that this new model recapitulates measured changes in AP, [Ca2þ ]
and [Naþ ] in response to ISO. Supplementary Fig. 7a shows the model schematic
and rodent-specific PKA targets, which includes: LTCC, slowly inactivating Kþ
current, ryanodine receptors, phospholemman, PLB, Inhibitor-1 and myofilament
proteins (TPNI, MyBPC, Titin). All simulations were performed in MATLAB (The
MathWorks, Natick, MA, USA) using the stiff ordinary differential equation solver
ode15 s. All source codes used in the paper are available online at https://
somapp.ucdmc.ucdavis.edu/Pharmacology/bers/.
Statistical analysis. Data are presented as means±s.e.m. Sample size was chosen
based on previous data to ensure adequate power to detect 10% difference.
Statistical analysis was performed with GraphPad Prism 5.0. The number of
technical and biological replicates is indicated in the figure legends. All groups that
were statistically compared showed equal variance. One-way ANOVAs with post
hoc test or unpaired two-tailed Student’s t-tests were used as appropriate. Statistical
significance, when achieved, is indicated as *Pr0.05, **Pr0.01, ***Pr0.001.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request. Source codes for the
entire mathematical model used in the paper are freely available online at:
https://somapp.ucdmc.ucdavis.edu/Pharmacology/bers/.
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